Lakewood-Amedex Biotherapeutics, Inc. (LABT)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Kelvin Cooper Ph.D.
|
CEO, SVP of Research & Development and Director | 190.42k | -- | 1956 |
|
Mr. Peter F. Ceccacci
|
CFO & VP of Administration | 160k | -- | 1955 |
|
Dr. Thomas Balzer M.D., Ph.D.
|
Chief Medical Officer & SVP of Clinical Development | 177.92k | -- | 1960 |
|
Ms. Tara Endress
|
Project Manager & Accounting Manager | -- | -- | -- |
|
Daniel Kontoh-Boateng
|
Investor Relations | -- | -- | -- |
Lakewood-Amedex Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 12, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
